RU2004114878A - Агенты, увеличивающие аффинность - Google Patents

Агенты, увеличивающие аффинность Download PDF

Info

Publication number
RU2004114878A
RU2004114878A RU2004114878/13A RU2004114878A RU2004114878A RU 2004114878 A RU2004114878 A RU 2004114878A RU 2004114878/13 A RU2004114878/13 A RU 2004114878/13A RU 2004114878 A RU2004114878 A RU 2004114878A RU 2004114878 A RU2004114878 A RU 2004114878A
Authority
RU
Russia
Prior art keywords
seq
binding protein
polypeptide
binding
residues
Prior art date
Application number
RU2004114878/13A
Other languages
English (en)
Russian (ru)
Inventor
Чиен-Хсинг Кен ЧАНГ (US)
Чиен-Хсинг Кен ЧАНГ
Эдмунд РОССИ (US)
Эдмунд РОССИ
Original Assignee
Иммуномедикс, Инк. (Us)
Иммуномедикс, Инк.
АйБиСи ФАРМАСЬЮТИКАЛЗ (US)
АйБиСи ФАРМАСЬЮТИКАЛЗ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иммуномедикс, Инк. (Us), Иммуномедикс, Инк., АйБиСи ФАРМАСЬЮТИКАЛЗ (US), АйБиСи ФАРМАСЬЮТИКАЛЗ filed Critical Иммуномедикс, Инк. (Us)
Publication of RU2004114878A publication Critical patent/RU2004114878A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2004114878/13A 2001-10-15 2002-10-15 Агенты, увеличивающие аффинность RU2004114878A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32883501P 2001-10-15 2001-10-15
US60/328,835 2001-10-15
US34188101P 2001-12-21 2001-12-21
US60/341,881 2001-12-21

Publications (1)

Publication Number Publication Date
RU2004114878A true RU2004114878A (ru) 2005-04-20

Family

ID=26986533

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004114878/13A RU2004114878A (ru) 2001-10-15 2002-10-15 Агенты, увеличивающие аффинность

Country Status (13)

Country Link
US (1) US20030113333A1 (enExample)
EP (1) EP1444267B1 (enExample)
JP (1) JP4443923B2 (enExample)
KR (1) KR101027889B1 (enExample)
CN (1) CN1604910A (enExample)
AU (1) AU2002335808B2 (enExample)
BR (1) BR0213284A (enExample)
CA (1) CA2463616C (enExample)
IL (1) IL161417A0 (enExample)
MX (1) MXPA04003533A (enExample)
PL (1) PL374426A1 (enExample)
RU (1) RU2004114878A (enExample)
WO (1) WO2003033653A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US6346454B1 (en) * 1999-01-12 2002-02-12 Agere Systems Guardian Corp. Method of making dual damascene interconnect structure and metal electrode capacitor
US20040018557A1 (en) * 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
EP1618181B1 (en) * 2003-04-22 2014-10-15 IBC Pharmaceuticals Polyvalent protein complex
KR20060041205A (ko) * 2003-07-01 2006-05-11 이뮤노메딕스, 인코오포레이티드 양특이성 항체들의 다가 담체들
EP3332808B1 (en) 2005-03-03 2020-09-09 Immunomedics Inc. Humanized l243 antibodies
ES2613844T3 (es) 2008-04-21 2017-05-26 Lawrence Livermore National Security, Llc Ligandos polidentados de alta afinidad selectivos y métodos para producirlos
WO2011003780A1 (en) * 2009-07-06 2011-01-13 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
US9264453B2 (en) 2013-11-08 2016-02-16 At&T Mobility Ii Llc Front end processor for short message service centers
KR20250150051A (ko) * 2023-03-03 2025-10-17 온코원 리서치 앤드 디벨롭먼트 게엠베하 과증식성 질환의 예비 표적화를 위한 개선된 이중특이적 항종양 항원/항hsg 항체

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
WO1994007921A1 (en) * 1992-09-25 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
EP0672142B1 (en) * 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
BR9606706A (pt) * 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
CA2249320C (en) * 1996-03-20 2008-12-23 Immunomedics, Inc. Glycosylated humanized b-cell specific antibodies
ES2225961T3 (es) * 1996-04-04 2005-03-16 Unilever N.V. Proteina de union a antigeno multivalente y multiespecifica.
JP4113670B2 (ja) * 1998-06-22 2008-07-09 イムノメディクス， インコーポレイテッド プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US20030162709A1 (en) * 2001-12-26 2003-08-28 Edmund Rossi Methods of generating multispecific, multivalent agents from VH and VL domains

Also Published As

Publication number Publication date
CA2463616C (en) 2011-07-12
WO2003033653A3 (en) 2003-11-13
KR20050036873A (ko) 2005-04-20
US20030113333A1 (en) 2003-06-19
WO2003033653B1 (en) 2004-02-12
KR101027889B1 (ko) 2011-04-07
PL374426A1 (en) 2005-10-17
EP1444267A2 (en) 2004-08-11
JP2005518344A (ja) 2005-06-23
WO2003033653A2 (en) 2003-04-24
CN1604910A (zh) 2005-04-06
AU2002335808B2 (en) 2009-08-27
JP4443923B2 (ja) 2010-03-31
EP1444267B1 (en) 2016-08-10
BR0213284A (pt) 2006-05-23
CA2463616A1 (en) 2003-04-24
MXPA04003533A (es) 2005-06-20
EP1444267A4 (en) 2009-12-02
IL161417A0 (en) 2004-09-27

Similar Documents

Publication Publication Date Title
RU2004122702A (ru) Способы получения полиспецифичных, поливалентных средств из vh и vl доменов
JP2021502810A5 (enExample)
Trachsel et al. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis
JP2005514030A5 (enExample)
Kang et al. Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate.
JPH04507195A (ja) 腫瘍壊死因子結合リガンド
DE69531148D1 (de) Bibliotheken aus polyklonalen antikörpern
JP2008508882A5 (enExample)
KR927003816A (ko) Cd3에 대한 항체
JP2007526233A5 (enExample)
JPH06510524A (ja) 免疫原性タンパク質をコードする遺伝子の標的への配達
JP2006511516A5 (enExample)
WO2013174264A1 (zh) 抗BLyS抗体
JP2001231555A (ja) 抗−プロカルシトニン抗体、その調製および使用
RU2004114878A (ru) Агенты, увеличивающие аффинность
JP2018504112A5 (enExample)
JP2008521426A5 (enExample)
CA2000913A1 (en) Family of high affinity antibodies for cancer treatment
JP2005528884A5 (enExample)
Shin et al. Functional and pharmacokinetic properties of antibody-avidin fusion proteins.
JP2003514772A (ja) Ｄｃｍを引き起こす自己抗体に対するペプチド
JPWO2020206330A5 (enExample)
JP2005518344A5 (enExample)
EP0525570A2 (en) Anti-idiotypic antibodies that mimic TNF
JP2003513985A (ja) 天然に存在しないエナンチオマー（Ｌ−ビオチン）を結合する抗体および該抗体のターゲッティング薬剤（ａｇｅｎｔ）としての使用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20070118